Life Sciences Archive » January, 2025

Life Sciences - January, 2025

317 articles

• Justices Implored To Consider Tipster Medical Device Row
• Pharmacy Escapes Novo Nordisk's Suit Over Ozempic
• January's IPO Market Was Active Despite Tepid Debuts
• Express Scripts Says FTC Tried To Swamp It With Lawsuits
• NY Doctor Charged In La. For Prescribing Abortion Pill Online
• Supreme Court Eyes Its 'Next Frontier' In FCC Delegation Case
• Litigation Funding Disclosure Debate: Strategy Considerations
• Judge Grants Fraud Retrial After Witness 'Forgot to Shut Up'
• Investors Say Walgreens Misled Over Prescription Misuse
• Law360 Seeks Members For Its 2025 Editorial Boards
• Trump Funding Freeze Blocked As Court Doubts Reversal
• 2025 May Be A Breakout Year For The Cannabis Industry
• Conn. Justices Let McCarter Ex-Client Off $3.6M Hook
• JAMS Adds AI-Focused Litigation Vet To Arbitration Team
• RFK Jr. Says He'll Give Stake In Merck Vaccine Case To Son
• Seasoned Patterson Belknap Trial Team Joins Linklaters In NY
• Taxation With Representation: Cravath, Gibson Dunn, Milbank
• FDA's Red No. 3 Ban Reshapes Food Safety Legal Landscape
• Trump's DEI Cuts Threaten USPTO Innovation Goals
• 4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined
• Pharmacy Says Its Ex-GC Destroyed Trade Secrets Evidence
• 2nd Circ. Sees No Skadden Conflict In Pharma Merger Work
• Plaintiffs, Pfizer Spar Over Where To Join Depo-Provera Suits
• Patent Lawyer Moves From DLA Piper To Kilpatrick
• Consumers Want L'Oréal Acne Products Suits In Hawaii
• Former Pharma Exec Gets 2 Months For Insider Trading
• DOJ Calls UnitedHealth Dismissal Bid A Discovery 'End Run'
• Scope And Nature Of Judicial Relief Will Affect Loper's Impact
• Samsung Gets PTAB To Review 2 Smart Ring Patents
• RFK Blasts Industry 'Puppets' Amid HHS Nomination Fight
• The Implications Of E-Cigarette Cos. Taking Suits To 5th Circ.
• Adventure Photography Makes Me A Better Lawyer
• NC Biz Court Bulletin: Sanctions Miss, Philip Morris Refund
• What Vinyl Acetate's Prop 65 Listing Means For Cos.
• Orrick Adds Head Of Antitrust Litigation From Weil
• Rumors Fly As Trump Seeks Deal To Keep TikTok Alive
• Cooley, Latham Steer Beta Bionics' Upsized $204M IPO
• Albertsons Must Face County's Opioid Nuisance Claims
• Fed. Circ. Affirms Delaying Biosimilars For Regeneron's Eylea
• BI Ignored 'Red Flag After Red Flag' On Zantac, Jury Hears
• Court Garbled Pharma Owner's Fraud Charges, 6th Circ. Told
• Labcorp Can't Flip Patent Board Loss At Fed. Circ.
• Farmers' Antitrust Claims Trimmed In Pesticides Case
• Fed. Circ. Inherency Ruling Refines Obviousness Framework
• Full Fed. Circ. Won't Allow MSN To Launch Generic Entresto
• Navigating The Potential End Of GLP-1 Drug Shortages
• Chinese Co. Execs Convicted Over Fentanyl Chemical Imports
• 9th Circ. Affirms Ax Of Patent Atty's Allergan FCA Fight
• 4 Questions About Trump's Federal Worker Resignation Policy
• High Court Could Further Limit Deference With TCPA Fax Case
• 5 Ways To Create Effective Mock Assignments For Associates
• White House Rescinds Trump's Spending Freeze
• RFK Jr. Disputes Anti-Vax Label In HHS Confirmation Hearing
• Trump Targets Gender-Affirming Care For Minors In New Order
• Minn. AG Settles Novo Nordisk Insulin Claims With Price Cap
• GSK Urges Del. Judge To Enhance $235M Skinny Label Win
• Founder Can't Explain Hedge Fund's Filing Mismatch To Jury
• Drugs Made In America SPAC Nets $200M To Buy Pharma Biz
• Pharma Co. Gets Final Shot To Ax NC Contract Breach Suit
• Questions To Watch For In RFK Jr.'s Confirmation Hearing
• 7th Circ. Considers Faith Of 2-Step Collective Certification
• Bain Capital Seeks Surgery Partners Buyout At $3.3B Value
• Trump Pledges Tariffs On Semiconductors, Chips, Drugs
• North Carolina Drug Testing Lab Inks $850K False Billing Deal
• Chinese Pair Sought To Fuel Fentanyl 'Grand Lab,' Feds Say
• Creditors Can Join Nostrum Sale Talks, Ch. 11 Judge Rules
• Calif. Cannabis Decision Deepens Commerce Clause Divide
• IVF Suits Highlight Need For Better Legal Frameworks
• 4 Firms Look To Build $1B Sale Of Evergreen Theragnostics
• Fund Tells Jury No Need To Return $11M Short-Swing Profits
• Takeda Pushes Meijer Antitrust Suit Into Arbitration
• Jury Will Decide $140M Intuitive Robo-Surgery Antitrust Case
• 2 Firms Want To Co-Lead Humacyte Investor Suit
• FOIA Lawsuit Seeks Marijuana Docs From Health Officials
• Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs
• Investors Sue Pharma Co. After Cancer Drug Trial Termination
• J&J Talc Unit's $9B Ch. 11 Plan Draws Slew Of Objections
• Novo Nordisk's Obesity Drug Study Allegedly Duped Investors
• Recent Suits Show Antitrust Agencies' Focus On HSR Review
• The 7th Circ.'s Top 10 Civil Opinions Of 2024
• Cencora CLO's Pay Package Nearly Doubled In 2024
• Royal Canin Ruling Won't Transform Removal Jurisdiction
• Justices Turn Away Venue Row In Zantac Carcinogen Claims
• Trump Revives Federal Anti-Abortion Policies
• Intuitive Doesn't Owe 'Free-Riding' Firm $140M, Expert Says
• Senate Bill Not Seen As Death Knell For Skinny Label Suits
• Pfizer To Pay $59M Over Unit's Migraine Drug Kickbacks
• Justices To Clarify Article III Standing For Certified Classes
• Ill. Justices OK Workers' Injury Suits Over Dormant Diseases
• Del. Justices Reject Investor Suit Over Dropped Drug Prospect
• IVF Patients Want CooperSurgical Embryo Loss Suits Joined
• Biotech Co. Defends Antitrust Counterclaims Against Rival
• Lessons From The Pharma Industry On Patent Cliffs
• Mentorship Resolutions For The New Year
• Venture-Backed IPO Recovery Could Be Muted, Report Says
• Intuitive Judge Walks Back 'Inappropriate' Witness Instruction
• 4th Circ. Reads Kickback Law Broadly In Loss For Big Pharma
• GoodRx, PBMs Sued Over Alleged Generics Price-Fix Scheme
• What Nearshoring Growth In Americas Means For Patents
• Unsigned Bladder Drug Patent Deal Not Binding, Judge Rules
• Ex-J&J Exec Accused Of File Theft Has Died, Court Told
• Takeaways From FDA's Updated Confirmatory Trial Guidance
• GenapSys Says Paul Hastings Can't Keep Privileged Docs
• Exactech Seeks Bonuses For Top Execs For Ch. 11 Sale
• The Most Important Schedule I Drug Regulatory Shifts Of 2024
• 15 States Reach $7.4B Settlement With Sackler Family
• Coaching Little League Makes Me A Better Lawyer
• Intuitive Chief Rejects Da Vinci Robot Market Monopoly Claim
• Fla. Court Proposes $19M In Damages In Spinal Products Suit
• Drug Co. Wants To Keep Judge On Alopecia IP Case
• RFK Filings Show Biopharma Stakes, Millions In Firm Income
• Fed. Circ. Stays Order Delisting Teva Inhaler Patents
• Vanda Loses Takings Clause Arguments In Trade Secret Fight
• No New Trial For Tevra's Flea, Tick Meds Suit Against Bayer
• Pharma Co. Says Ex-CEO's Alleged Misconduct Is Not Fraud
• Fed. Circ. Backs Ravgen's Genetic Testing Patent
• Benzene Suits Against Retailers Not Covered, Insurer Says
• 9th Circ. Won't Revive Express Scripts Generics Dispute
• Wyden Urges National Standard For Hemp Regulation
• 5 Litigation Funding Trends To Note In 2025
• Cooley-Led Insulin Device Maker Preps $113M IPO
• Nixed Invitae Asset Buyer Asks Ch. 11 Court To Stop Litigation
• Key Justices Stay Quiet As High Court Weighs FCC Deference
• Intuitive Seeks Midtrial End To Robo-Surgery Antitrust Suit
• The Legal And Practical Questions Around Trump's WHO Exit
• A Look At FDA's Plans To Establish New OTC Drug Category
• Last Sackler Family Members Join Purdue Draft Deal
• Bacon Giant Smithfields Leads 3 IPOs Primed To Exceed $1B
• Trump Taps Pot Legalization Opponent As Acting DEA Head
• Justices Doubt Retailers Are 'Bystanders' In FDA Challenge
• Firm Slams Beasley Allen's Bid To Nix Suit Over Talc Team-Up
• The Fed. Circ. In 2024: 5 Major Rulings To Know
• What IP Attorneys Need To Know From Trump's First Days
• Law360 Names Practice Groups Of The Year
• Law360 Names Firms Of The Year
• Trump, Musk Sued By Nonprofits Over DOGE Transparency
• Walgreens Knowingly Filled Invalid Prescriptions, Feds Say
• MSN Wants Generic Entresto Launch After Patent Expired
• Bayer, J&J Minimized Drug Reaction Data, 3rd Circ. Told
• Up Next At High Court: Forum Shopping & TCPA Definitions
• NC Biotech Co. Can't Restrain Co-Founder's Rival Biz Yet
• 3rd Circ. Vexed By Remedies For Defunct Vax Mandate
• Rethinking Litigation Risk And What It Really Means To Win
• Duke U. Strikes Deal In Female Scientist's Pay Bias Suit
• Crown Labs Tops Rival Bid In Quest To Buy Biotech Revance
• 1st Circ. Revives Biotech Worker's COVID-19 Vax Challenge
• Taxation With Representation: Simpson Thacher, Covington
• Texas Judge Says 3 States Can Pursue Mifepristone Suit
• ITC Commissioner Heading To WilmerHale In DC
• EpiPen Direct Buyers, Mylan Ink $75M Antitrust Deal
• USPTO Seeks Views On 'Traditional Knowledge' IP Treaty
• How DOGE's Bite Can Live Up To Its Bark
• Expert Witnesses Limited In J&J Talc Ch. 11 Dismissal Try
• Merck Defends 3rd Circ. Win In Mumps Vaccine Antitrust Case
• Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug
• NC Biz Court Bulletin: Judge Bids Adieu, TikTok Wants Out
• Chamber Slams Opioid Judge's PBM Audit Privilege Ruling
• US-China Deal Considerations Amid Cross-Border Uncertainty
• Considering The Status Of The US Doctrine Of Patent Misuse
• Playing Rugby Makes Me A Better Lawyer
• Novartis Wins Temporary Stay Of MSN's Generic Heart Drug
• Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal
• Robo Surgery Co. Caused $140M In Lost Profits, Jury Told
• Quest Diagnostics Gets Meta Data-Share Suit Tossed For Now
• SEC Dings Pharma Co., Ex-CFO Over Prescription Scheme
• Abbott's Toddler Nutrition Drinks Aren't Healthy, Parents Claim
• Justices Asked If Zoning Immunity Can Pass To Private Entity
• Del. Justices Mull 'Reasonable' Effort Duty In Drug Biz Deal
• DOJ Reports $2.9B Haul Under FCA, Largest In 3 Years
• 3rd Circ. Preview: NFL Concussion Benefits Fight Tops January
• Looking Back At 2024's Noteworthy State AG Litigation
• Chinese Execs Sent Fentanyl Precursor To NY, Jury Told
• Former FDA Official Joins King & Spalding Life Sciences Team
• No, Litigation Funders Are Not 'Fleeing' The District Of Del.
• Patent Policy Changes To Track Under New Gov't Leadership
• FDA Bans Red Dye No. 3, Citing Cancer Link In Animal Studies
• Holland & Knight Adds Ex-GOP Rep. To Policy Advisory Team
• Justices Say Nixing Federal Claims Ends Federal Jurisdiction
• Abbott, Novartis Settle HIV Test Patent Beef Ahead Of Trial
• Conn. City Hits PBMs And Pharma Cos. With Insulin Pricing Suit
• Latham Grabs Top Spot For 2024 IPOs By Large Margin
• Fed. Circ. Judge Asks What's The Rush In Eylea Biosimilar Case
• Chancery Hits Co. With $2.9M Atty Fee Bill As Sanction
• Cannabis Reformers Split After DEA Judge Cancels Hearings
• Dispute Over Eli Lilly Weight Loss Drug Reignited
• SEC Sues Elon Musk Over Late Twitter Buy-Up Disclosure
• Liability Risk For AI In Medical Devices Demands Greater Care
• 5 E-Discovery Predictions For 2025 And Beyond
• Eli Lilly Says Colo. Clinic Selling Deceptive Weight Loss Drug
• TikTok Says NC Can't Fault Platform For Being 'Too Engaging'
• MIT Bio Lab Can't Use Anti-SLAPP To Duck Defamation Suit
• Mass. AG Says Insulin Makers, Middlemen Colluded On Costs
• Robo-Surgery Part Reset Is Reliable, Expert Tells Antitrust Jury
• Ozempic Maker Says Atlanta Clinic Misuses TM To Sell Meds
• 5 Firms Steer Up-To-$750M Sale Of Life Molecular Imaging
• Acting USPTO Chief Won't Review Seed IP Challenge Denial
• Goodwin Procter Adds NY IP Attys From Fenwick, Desmarais
• 4 Trade Secret Developments To Follow This Year
• Lilly To Buy Scorpion Cancer Program For Up To $2.5B
• Republican Trifecta Amplifies Risks For Cos. In 3 Key Areas
• PBMs' Federal Work Irrelevant To Opioid Suit, Mich. AG Says
• Cravath-Led J&J Paying $14.6B For Neuropsychiatric Drug Co.
• Feds Say NC Medical Biz Owner Overbilled For Nutrient Drinks
• Supreme Court Turns Away IP Safe Harbor Dispute
• Nvidia's Healthcare Ambitions Grow In New Partnerships
• Intuitive Rips VP's Credibility In Robo-Surgery Antitrust Trial
• GSK Hits Back At Moderna Counterclaims In Patent Feud
• Masimo, Apple Fight Over Watch IP In Post-Bench Trial Briefs
• AstraZeneca Widens Blockbuster Cancer Drug Patent Fight
• Fed. Circ. Revives Novartis Entresto Patent In MDL
• 4 Trends That Will Shape Venture Capital Funding In 2025
• 9th Circ. Affirms Hearing Aid Co.'s Win Over Investor Suit
• What's Next After Fed. Circ. Limits Orange Book Listings?
• FDA Tells Justices RJ Reynolds Challenge Belongs In DC Circ.
• Ex-CEO's Sentencing In COVID Test Securities Fraud Delayed
• J&J Talc Claimants Seek Sanctions Over Morelli No-Show
• Ex-McKinsey Partner Admits To Obstructing Purdue Probe
• UK Litigation Roundup: Here's What You Missed In London
• Illinois Adds 4 Conditions To Medical Pot Eligibility List
• Taxation With Representation: Kirkland, Davis Polk, Wachtell
• 7 Ways 2nd Trump Administration May Affect Partner Hiring
• BCLP's Global Healthcare Chair Jumps To Dechert
• 'Stunned': Judge Rips Atty For Violating Antitrust Trial Order
• Catalyst Settles Patent Fight Against Teva Over Firdapse
• IP Forecast: OpenAI, Microsoft Look To Toss NYT Case
• Amgen Says Enbrel Protected By Legit Patents, Rulings
• Kroger Accused By Calif. AG Of Ignoring Opioid 'Red Flags'
• Pharma Co. Says Ex-CEO's Bias Allegations Come Up Short
• Cancer Org Fails To Get Rival's TM Counterclaims Tossed
• J&J Spin-Off Says Talc Committee Can't Hire Brown Rudnick
• New Mexico Justices Say Local Gov'ts Can't Restrict Abortion
• Stem Cell Therapy Co. Hit With $5.1M Deceptive Ad Judgment
• How Trump 2.0 May Change Business In Latin America
• Courts Must Curb The Drug Price Negotiation Program
• E-Discovery Quarterly: Rulings On Custodian Selection
• Ropes & Gray Reps Valspring Capital On Debut $255M Fund
• Ropes & Gray-Led Vistria Wraps Largest-Ever Fund At $3B
• Embryo Loss Suits Against CooperSurgical Mount In Conn.
• Intuitive Killed Biz For Reusing Robo-Surgery Arms, Jury Told
• Meta, Microsoft, Google Seek To Toss DNA Data-Sharing Suit
• UnitedHealth Wants $3.3B Amedisys Deal Challenge Tossed
• Patent Board Knocks Out Most Of Apple Patent
• USTR Warns Of Risks Posed By Counterfeit Pharmacies
• Biotech Co.'s Facility Failures Lost Investors Money, Suit Says
• EPA Slams $535M Talc Settlement In Whittaker's Ch. 11
• 3 Firms Steer Galapagos' Plan To Spin Off New Drug Company
• Ex-Marketing Exec Says J&J Unit Dodging Basic Discovery
• Buchanan Ingersoll Adds Frier Levitt Pharmacy Atty In NJ
• FBI Director's Former Chief Of Staff Joins Fenwick
• Abbott Beats UC Regents' Probiotic Patent Claims
• Boston Scientific Paying Up To $664M For Bolt Medical
• Exercising On My Peloton Bike Makes Me A Better Lawyer
• Obesity Drug Maker Faces Investor Suit Over IPO Disclosures
• Robo Surgery Co. Gets Billions From Selling Parts, Jury Told
• Alcohol Warnings Unlikely To Bring Same Fate Tobacco Faced
• Amneal Calls Teva's IP Delisting Panic 'Theatrical Distraction'
• New USPTO Advisers Include Mattel, Estee Lauder Attys
• Cannabis Reformers Move To Oust DEA From Pot Hearings
• Biotech Co. Urges NC Panel To Revive Legal Malpractice Suit
• 5 Drug And Device Developments That Shaped 2024
• How To Manage During A Trade Dispute With USMCA Partners
• Rejoinder Strategy After Allergan Double-Patenting Case
• Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud
• Sidley, Wachtell Guide Inari Medical's $4.9B Sale To Stryker
• High Court Asked To Take Whistleblower Medical Device Row
• Biotech Trade Secrets Case Gets New Punitive Damages Trial
• Biotech Co. Revance Faces Suit After Tender Offer Weakens
• DOD Adds WeChat Owner, CATL To Chinese Military Co. List
• Labcorp Loses Appeal Of Gene-Testing Patent In $372M Case
• Judge Urged To Sit Out Alopecia IP Row Over Ex-Clerk's Role
• Teoxane Outbids Crown With New Revance Therapeutics Bid
• Takeaways From 2024's Emerging IP Licensing Trends
• Exploring Venue Strategy For Trump-Era Regulatory Litigation
• Girard Sharp Launches Into New Year With New Leadership
• Vizgen Loses Antitrust Claims Against 10x In Biotech IP Fight
• Ex-Locke Lord IP Pros To Build Buchanan Chicago Office
• Natera Loses New Trial Bid After Winning $96M Patent Verdict
• Aetna Says Takeda Inked Deal To Block Generics, Keep Profits
• DOJ Wants Oct. Amedisys Trial, UnitedHealth Wants Aug.
• PBMs 'Wasting' Time in Opioid MDL Discovery Spat: Judge
• Cancer Drug Co. Revives Bid To Go Public Via Direct Listing
• Consultants Should Be Aware Of DOJ's Potential New Reach
• Pfizer Partner Targets GSK In COVID Vax Patent Suit
• Lessons Learned From 2024's Top FMLA Decisions
• Fed. Circ. Upholds Cancellation Of TMs On Pink Hip Implants
• $15M Flea Collar MDL Deal Scores Swift Approval By Ill. Judge
• Biogen Not On Hook For Disruptions Caused By Landlord
• Research Co. Can't Ax Affair Harassment Suit, Ex-Worker Says
• Eye Drug Study Blindsided Pharma Co. Investors, Suit Says
• Fox Rothschild Atty Beats Trade Secret Theft Allegations
• Edwards Brass Face Investor Suit Over Heart Valve Sales
• Issa Again Selected To Lead House IP Subcommittee
• 1st Private Co. Joins Insulin Price-Fixing MDL
• A-Rod's SPAC Deal Seeks Extra Innings, Plus More IPOs Filed
• Product Safety Issues In 2024 Highlight Need For Vigilance
• Ozempic Caused Severe Pain And Hospitalization, Suit Says
• Eli Lilly Slams Suit Alleging Shortage Of Weight-Loss Drug
• Hikma Wants Extension At High Court In Skinny Label Case
• Playing Esports Makes Me A Better Lawyer
• Roche Strikes $80M Oncology Drug Deal With Chinese Biotech
• 'Crush-Resistant' OxyContin Patents Fail At Fed. Circ.
• Aetna Sues Drugmakers In Conn., Alleging Generics Price-Fixing
• Beasley Allen Aims To Toss Suit From Ex-Ally Firm
• IRS, Treasury Float Regs On Excise Taxes For Drugmakers
• Healthcare and Life Science Deals Attys Expect In 2025
• Health Tech Regulatory Trends To Watch In 2025
• An Associate's Guide To Career Development In 2025
• The Top 5 High Court Cases To Watch This Spring
• Healthcare And Life Science Policies To Watch In 2025
• High-Stakes Healthcare Court Battles To Watch In 2025
• Product Liability Cases To Watch In 2025
• Patent Policy To Watch In 2025
• 2025 Patent And TM Policy At USPTO: What We Know So Far
• IPO Outlook Brightens As More Companies Eye 2025 Listings
• Patent Cases To Watch In 2025
• Top Federal Tax Cases To Watch In 2025
• Patent Litigation Trends To Watch In 2025